Tessa joint venture to develop cancer cell therapies in China

Strategy developed to target metastases in lymph nodes
Credit: Shutterstock.com/ Syda Productions

Singaporean cell therapy specialist, Tessa Therapeutics, and Guangzhou Knowledge City (CSGKC) are forming a joint venture to licence the former’s cell therapies for research, clinical development and commercialisation in China.

The organisations will invest a combined total of $120 million in the joint venture – CSGKC will contribute $80 million and Tessa will provide $40 million – in two stages.

In the first stage, CSGKC will contribute $40 million for 13% stake in the joint venture, while Tessa will contribute $20 million and its technology license rights for China.

Tessa will hold the remaining 87% stake in the joint venture.

“China is an important market in our goal to develop innovative cell therapies and make them widely accessible for cancer patients all over the world,” said Andrew Khoo, Tessa Therapeutics CEO and Co-Founder.

“The joint venture is an important milestone in Tessa’s China strategy and will draw from Tessa’s international clinical execution capability and cell therapy platform technologies.

“I firmly believe that having China as a core part of Tessa’s global clinical development strategy will accelerate our cell therapies to market.”

The joint venture’s immediate strategic priorities will focus on conducting clinical trials in China for Tessa’s cell therapies, which target prevalent cancers in the country for patients with haematological malignancies and solid tumours.

This will be done by building up robust operational capabilities and adding leading clinical trial sites in China into Tessa’s global clinical trial network.